Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of EBITDA data on record, last reported at -$36.7 million in Q3 2025.

  • For Q3 2025, EBITDA fell 50.07% year-over-year to -$36.7 million; the TTM value through Sep 2025 reached -$126.9 million, down 91.04%, while the annual FY2024 figure was -$84.9 million, 95.88% down from the prior year.
  • EBITDA reached -$36.7 million in Q3 2025 per DNTH's latest filing, down from -$31.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.0 million in Q1 2023 and bottomed at -$36.7 million in Q3 2025.
  • Average EBITDA over 4 years is -$19.6 million, with a median of -$17.4 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 70.14% in 2023, then crashed 176.02% in 2024.
  • A 4-year view of EBITDA shows it stood at -$10.1 million in 2022, then decreased by 3.8% to -$10.5 million in 2023, then crashed by 176.02% to -$29.0 million in 2024, then fell by 26.49% to -$36.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$36.7 million in Q3 2025, -$31.8 million in Q2 2025, and -$29.3 million in Q1 2025.